The dual role of IL-10

Trends in Immunology

Volumn 24, Issue 1, 2003, Pages 36-43

  Mocellin, Simone ^a   Panelli, Monica C ^b   Wang, Ena ^b   Nagorsen, Dirk ^b   Marincola, Francesco M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD30 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE ELASTASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER INHIBITION; CROHN DISEASE; GENETIC ANALYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LEISHMANIA; LISTERIA MONOCYTOGENES; LUNG CARCINOMA; MELANOMA; MOUSE; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; PHAGOCYTOSIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE LEVEL; TUMOR REGRESSION; TUMOR REJECTION; UPREGULATION; WILD TYPE;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; INFLAMMATION; INTERLEUKIN-10; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 0037213614     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)00009-1     Document Type: Review

References (65)

1. Cavaillon J.M. Pro- versus anti-inflammatory cytokines: myth or reality. Cell Mol. Biol. 47:2001;695-702.
2. Byrne A., Reen D.J. Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Immunol. 168:2002;1968-1977.
3. Huang Q., et al. The plasticity of dendritic-cell responses to pathogens and their components. Science. 294:2001;870-875.
4. Langenkamp A., et al. Kinetics of dendritic-cell activation: impact on priming of Th1. Th2 and nonpolarized T cells. Nat. Immunol. 1:2000;311-316.
5. 2, Fas ligand and TNF-related apoptosis-inducing ligand. J. Immunol. 168:2002;1831-1839.
6. Fanger N.A., et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis inducing ligand (TRAIL). J. Exp. Med. 190:1999;1155-1164.
7. Blanco L., et al. Effect of Salmonella-infected human monocytes on natural killer-cell cytotoxicity in vitro studies. Int. Immunopharmacol. 1:2001;1285-1293.
8. Gerosa F., et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195:2002;327-333.
9. Albert M.L., et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
10. Ignatius R., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor α secretion. J. Virol. 74:2000;11329-11338.
11. Gerard C.M., et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum. Gene Ther. 7:1996;23-31.
12. Zheng L.M., et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184:1996;579-584.
13. Kundu N., et al. Antimetastatic and antitumor activities of interleukin-10 in a murine model of breast cancer. J. Natl Cancer Inst. 88:1996;536-541.
14. Parato K.G., et al. Normalization of natural killer-cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS. 16:2002;1251-1256.
15. Lauw F.N., et al. Proinflammatory effects of IL-10 during human endotoxemia. J. Immunol. 165:2000;2783-2789.
16. Petersson M., et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. 161:1998;2099-2105.
17. Salazar-Onfray F., et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. 154:1995;6291-6298.
18. Janjic B.M., et al. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J. Immunol. 168:2002;1823-1830.
19. Kelly J.M., et al. Induction of tumor-specific T-cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3:2002;83-90.
20. Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23:2002;201-208.
21. Moore K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:2001;683-765.
22. Di Carlo E., et al. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur. Cytokine Netw. 9:1998;61-68.
23. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
24. Pietra G., et al. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res. 61:2001;8218-8226.
25. Brossart P., et al. Tumor necrosis factor α and CD40 ligand antagonize the inhibitory effects of interleukin-10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60:2000;4485-4492.
26. Kuhn R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:1993;263-274.
27. Shull M.M., et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
28. Cua D.J., et al. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 189:1999;1005-1010.
29. Lee C.G., et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation and airway remodeling via IL-13-dependent and -independent pathways. J. Biol. Chem. 277:2002;35466-35474.
30. Rohrer J.W., Coggin J.H. Jr. CD8 T-cell clones inhibit anti-tumor T-cell function by secreting IL-10. J. Immunol. 155:1995;5719-5727.
31. Llorente L., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:2000;1790-1800.
32. Asadullah K., et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101:1998;783-794.
33. Schreiber S., et al. Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology. 119:2000;1461-1472.
34. Miura Y., et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GvHD): interleukin 10 and interferon-γ may be critical mediators for the development of autologous GvHD. Blood. 100:2002;2650-2658.
35. Olszyna D.P., et al. Interleukin-10 inhibits the release of CC chemokines during human endotoxemia. J. Infect. Dis. 181:2000;613-620.
36. Pajkrt D., et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J. Immunol. 158:1997;3971-3977.
37. Chernoff A.E., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154:1995;5492-5499.
38. Mocellin S., et al. Cytokine and immune response in the tumor microenvironment. J. Immunother. 24:2001;392-407.
39. Huang S., et al. Interleukiin-10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 2:1996;1969-1979.
40. Kaufman H.L., et al. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. 22:1999;489-496.
41. Berman R.M., et al. Systemic administration of cellular IL-10 induces an effective, specific and long lived immune response against established tumors in mice. J. Immunol. 157:1996;231-238.
42. Barth R.J., et al. In vivo effects of locally secreted IL-10 on the murine antitumor immune response. Ann. Surg. Oncol. 3:1996;381-386.
43. Fujii S., et al. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood. 98:2001;2143-2151.
44. Adris S., et al. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther. 6:1999;1705-1712.
45. Stearns M.E., et al. Interleukin-10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin. Cancer Res. 5:1999;189-196.
46. Giovarelli M., et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155:1995;3112-3123.
47. Richter G., et al. Interleukin-10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53:1993;4134-4137.
48. Enk A.H., et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer. 73:1997;309-316.
49. Conrad C.T., et al. Differential expression of transforming growth factor β1 and interleukin-10 in progressing and regressing area of primary melanoma. J. Exp. Clin. Cancer Res. 18:1999;225-232.
50. Yue F.Y., et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer. 71:1997;630-637.
51. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:1997;165-177.
52. Marincola F.M., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181-273.
53. + cytotoxic T lymphocytes. J. Virol. 74:2000;4729-4737.
54. Wang E., Marincola F.M. A natural history of melanoma: serial gene expression analysis. Immunol. Today. 21:2000;619-623.
55. Mocellin S., et al. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer. 93:2001;236-242.
56. Wang E., et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:2002;3581-3586.
57. Panelli M.C., et al. Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 3:2002;. RESEARCH0035.
58. Levy B.D., et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:2001;612-619.
59. McInnes I.B., et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol. 167:2001;4075-4082.
60. Keystone E., et al. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24:1998;624-635.
61. Nelson D.R., et al. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon non-responders. Gastroenterology. 118:1998;655-660.
62. Tao M., et al. In vivo effects of IL-4, IL-10 and aminofostine on cytokine production in patients with acute myelogenous leukemia. Leuk. Lymphoma. 41:2001;161-168.
63. Chakraborty A., et al. Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. J. Clin. Pharmacol. 39:1999;624-635.
64. Huang S., et al. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res. 19:1999;697-703.
65. Velardi A., et al. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 3:2002;438-444.